Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuyang
Clinical trial register · China

Clinical Trials in Fuyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital5 AstraZeneca3 Capital Medical University3 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3 The Second Hospital of Anhui Medical University2
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Fuyang

46 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Xinqiao Hospital of Chongqing
Phase 2/3
1,192
Fuyang, Longyan, Xiangtan, Ganzhou, Jingdezhen, Jiujiang, Dalian, Mianyang
2026-12-19
Recruiting
Novo Nordisk A/S
Phase 4
300
Fuyang, Beijing, Lanzhou, Huizhou, Shantou, Shijiazhuang, Anyang, Yichang
2026-10-12
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
50
Fuyang, Zhengzhou, Zhoukou, Huaian, Yancheng, Meihekou, Shanghai
2026-09-23
Recruiting
Antengene Biologics Limited
Phase 3
380
Bengbu, Fuyang, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei
2026-09-17
Not yet open
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Not yet open
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Not yet open
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599Ischemic Cerebral Infarction
Beijing Tiantan Hospital
Phase 3
4,810
Fuyang, Wuhu, Beijing, Chongqing, Ningde, Dingxi, Jiuquan, Lanzhou
2026-04-22
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Active, closed
Capital Medical University
Not applicable
208
Fuyang, Suzhou, Beijing, Zhoukou, Shihezi
2025-12-18
Recruiting
Capital Medical University
Phase 3
1,192
Anqing, Bozhou, Fuyang, Ma’anshan, Suzhou, Wuhu, Beijing, Fuzhou
2025-12-18
Not yet open
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
130
Fuyang, Beijing, Ulanhot, Ürümqi
2025-10-10
Active, closed
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Active, closed
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
981
Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang
2025-06-20
Recruiting
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Not yet open
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Recruiting
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
Anhui Provincial Hospital
Observational
10,000
Anqing, Bengbu, Bozhou, Chizhou, Chuzhou, Fuyang, Hefei, Huaibei
2025-01-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Recruiting
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-16
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-10
Active, closed
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Active, closed
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
DrugsAmlodipine besylate and folic acid·Amlodipine besylate·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Anhui Provincial Hospital
Phase 2
45
Fuyang, Hefei
2024-07-20
Recruiting
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
NCT06449937Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
Anhui Provincial Hospital
Not applicable
130
Chuzhou, Fuyang, Hefei, Ma’anshan, Wuhu
2024-07
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 2
226
Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang
2024-04-08
Recruiting
Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion
NCT06155032Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
First Affiliated Hospital of Wannan Medical College
Not applicable
272
Fuyang, Hefei, Huainan, Huangshan City, Suzhou, Wuhu, Xiangyang
2024-01-04
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Active, closed
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Active, closed
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/fuyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Fuyang.

How many clinical trials are recruiting in Fuyang?

28 of the 46 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuyang), 46 studies
PhaseStudiesRecruitingShare
Phase 317937%
Not applicable8517.4%
Phase 27615.2%
Phase 47415.2%
Phase 2/3316.5%
Observational224.3%
Phase 1/2214.3%

Most active sponsors

Lead sponsors with the most studies (Fuyang)
Lead sponsorStudiesRecruiting
Anhui Provincial Hospital55
AstraZeneca31
Capital Medical University31
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.32
Biogen22
Hangzhou Gensciences Biopharmaceutical Co., Ltd.20
Shenzhen Ausa Pharmed Co.,Ltd22
The Second Hospital of Anhui Medical University22
Antengene Biologics Limited11
Beijing Tiantan Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.